For the quarter ending 2025-09-30, SBFMW made $9,417,179 in revenue. -$1,485,448 in net income. Net profit margin of -15.77%.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Revenue | 9,417,179 | 9,410,230 | ||
| Cost of sales | 6,343,639 | 5,987,364 | ||
| Gross profit | 3,073,540 | 3,422,866 | ||
| Accounting | 135,413 | 75,611 | ||
| Consulting | 159,003 | 736,727 | ||
| Director fees | 100,000 | 100,000 | ||
| Legal | 193,009 | 64,995 | ||
| Marketing | 235,217 | 201,658 | ||
| Office | 614,661 | 806,605 | ||
| R&d | 119,298 | 196,232 | ||
| Salaries | 1,833,172 | 2,048,676 | ||
| Taxes | 119,909 | 112,675 | ||
| Impairment of intangible assets | 554,650 | 1,061,809 | ||
| Depreciation | 95,821 | 72,533 | ||
| Total g & a | 4,160,153 | 5,477,521 | ||
| (loss) from operations | -1,086,613 | -2,054,655 | ||
| (loss) on asset sale | -10,250 | - | ||
| Foreign exchange gain (loss) | 253 | 1,940 | ||
| Interest income | 75,352 | 72,715 | ||
| Interest expense | 0 | 0 | ||
| Total other income (expenses) | 65,355 | 74,655 | ||
| Net (loss) before income taxes | -1,021,258 | -1,980,000 | ||
| Provision for income taxes | -137,438 | -209,166 | ||
| Net (loss) | -883,820 | -1,770,834 | ||
| Gain (loss) from foreign exchange translation | -601,628 | 1,084,557 | ||
| Comprehensive (loss) | -1,485,448 | -686,277 | ||
| Earnings per share, diluted | - | -0.82 | ||
| Weighted average number of shares outstanding, diluted | - | 3,604,653 | ||
| Basic (loss) per common share | -0.19 | -0.39 | ||
| Weighted average common shares outstanding (basic) | 4,555,945 | 4,496,108 | ||
Sunshine Biopharma Inc. (SBFMW)
Sunshine Biopharma Inc. (SBFMW)